SCHEMBL25260413

SCHEMBL25260413

COc1cccc(-c2nccc(Cl)n2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 12/20 0.68
DYRK1A Q13627 4/20 0.68
CYP1A2 P05177 11/20 0.56
CYP3A4 P08684 10/20 0.56
CYP2D6 P10635 9/20 0.56
CYP2C19 P33261 9/20 0.56
LMNA P02545 5/20 0.56
TP53 P04637 4/20 0.56
MAPK1 P28482 3/20 0.56
MAPT P10636 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
TDP1 Q9NUW8 3/20 0.56
TSHR P16473 5/20 0.55
ALDH1A1 P00352 4/20 0.55
MEN1 O00255 3/20 0.55
ALOX15 P16050 3/20 0.55
KMT2A Q03164 3/20 0.55
CYP19A1 P11511 1/20 0.55
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31230006 1.00 CLK4 (0.68) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL28029638 0.84 CLK4 (0.72) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL4126244 0.83 CLK4 (0.61) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL25269044 0.83 CLK4 (0.70) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL2666349 0.83 CLK4 (0.70) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL31230014 0.83 CLK4 (0.70) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL12302829 0.81 CLK4 (1.00) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL25220297 0.81 CLK4 (0.68) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL30447335 0.81 CLK4 (0.68) CLK4DYRK1ACYP1A2CYP3A4CYP2D6
SCHEMBL25267391 0.79 CLK4 (0.64) CLK4DYRK1ACYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250288589-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. 2025-09-18 US disclosed
US-20250145642-A1 BICYCLIC HETEROARENES AND METHODS OF THEIR USE Kineta, Inc. 2025-05-08 US disclosed
EP-4444317-A2 BICYCLIC HETEROARENES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 EP disclosed
EP-4444289-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 EP disclosed
WO-2023107592-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
WO-2023107592-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
WO-2023107623-A2 BICYCLIC HETEROARENES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed
WO-2023107623-A2 BICYCLIC HETEROARENES AND METHODS OF THEIR USE Kineta, Inc. (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250288589-A1 PYRIDOPYRIMIDINES AND METHODS OF THEIR USE PNPO, DPYD, PYGB CLK4 3285/4885DYRK1A 2379/4885CYP1A2 837/4885
US-20250145642-A1 BICYCLIC HETEROARENES AND METHODS OF THEIR USE TARDBP, TDP2, PSEN2 CLK4 1587/4885DYRK1A 1435/4885CYP1A2 2748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.